Friday, February 1, 2019

The U.S. Food and Drug Administration (FDA) approved Mylan NV's generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday.


from Reuters: Health News https://reut.rs/2SfFFd3

Related Posts:

  • LATEST HEALTH NEWS(Reuters Health) - Many breast cancer patients may miss out on genetic tests that could help pinpoint the ideal treatment regimen at least in part because their surgeons are uncomfortable discussing the pros and cons of these… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Folic acid fortification not only protects developing babies against certain birth defects but also supports healthy brain development through the teenage years, researchers report. from Reuters: Healt… Read More
  • LATEST HEALTH NEWSLONDON (Reuters) - Britain moved a step closer to legalizing the medicinal use of cannabis after a report concluded there are benefits for patients as the government reviews the rules to allow drugs derived from the banned pl… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Women who struggle to get pregnant or use reproductive technologies like in vitro fertilization (IVF) may be more likely to have preemies and kids with birth defects than their peers who conceive without di… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Minor strokes and "mini-strokes," or transient ischemic attacks (TIAs), need early medical attention, just like major strokes, but a public education campaign in the UK had little success convincing the pub… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner